Lisa K Dunnwald

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
  2. pmc Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
    Lisa K Dunnwald
    Department of Epidemiology, University of Washington, Box 356113, 1959 NE Pacific St, Seattle, WA 98195, USA
    Breast Cancer Res 9:R6. 2007
  3. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
  4. ncbi request reprint Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival
    Lisa K Dunnwald
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    Cancer 103:680-8. 2005
  5. ncbi request reprint Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
  6. ncbi request reprint Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
  7. ncbi request reprint 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy
    Jeffrey Tseng
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195 6113, USA
    J Nucl Med 45:1829-37. 2004
  8. pmc Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 32:1124-31. 2010
  9. ncbi request reprint [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002
  10. pmc Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer
    Jennifer M Specht
    Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 16:2803-10. 2010

Detail Information

Publications20

  1. pmc PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake
    Lisa K Dunnwald
    Division of Nuclear Medicine and Medical Oncology, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:2400-9. 2011
    ..Serial dynamic [(18)F]-FDG (fluorodeoxyglucose) PET scans were used to compare kinetic parameters with the standardized uptake value (SUV) as predictors of pathologic response, disease-free survival (DFS), and overall survival (OS)...
  2. pmc Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
    Lisa K Dunnwald
    Department of Epidemiology, University of Washington, Box 356113, 1959 NE Pacific St, Seattle, WA 98195, USA
    Breast Cancer Res 9:R6. 2007
    ..However, few studies have evaluated variations in the risks of breast cancer-specific mortality across ER/PR status by either demographic or clinical characteristics...
  3. pmc Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
    ..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
  4. ncbi request reprint Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival
    Lisa K Dunnwald
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    Cancer 103:680-8. 2005
    ..The pathologic response of LABC to presurgical treatment regimens is a prognostic indicator of survival. The authors tested whether MIBI uptake posttherapy predicted survival...
  5. ncbi request reprint Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
    ..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
  6. ncbi request reprint Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
    ..To characterize in vivo tumor biology in patients with LABC, we performed serial measurements of blood flow and glucose metabolism in LABC patients over the course of neoadjuvant chemotherapy and compared measurements with response...
  7. ncbi request reprint 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy
    Jeffrey Tseng
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195 6113, USA
    J Nucl Med 45:1829-37. 2004
    ..The aim of this study was to characterize the biologic response of locally advanced breast cancer (LABC) to chemotherapy using (15)O-water-derived blood flow measurements and (18)F-FDG-derived glucose metabolism rate parameters...
  8. pmc Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Savannah C Partridge
    Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98109 1023, USA
    J Magn Reson Imaging 32:1124-31. 2010
    ....
  9. ncbi request reprint [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002
    ..To determine the influence of breast tumor blood flow on MIBI kinetics, we compared MIBI uptake and washout to [O-15]-water PET estimates of blood flow in patients with locally advanced breast cancer...
  10. pmc Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer
    Jennifer M Specht
    Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 16:2803-10. 2010
    ..This analysis examines tumor metabolism and perfusion by tumor subtype...
  11. pmc Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF
    Robert K Doot
    Department of Bioengineering, University of Washington, Seattle, Washington, USA
    J Nucl Med 48:920-5. 2007
    ..We tested whether chemotherapy and treatment with granulocyte colony-stimulating factor (CSF) changed the blood clearance curves and therefore affected the relationship between MRFDG and SUV...
  12. pmc Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer
    Peter R Eby
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G3 200, Seattle, WA 98109 1023, USA
    Acad Radiol 15:1246-54. 2008
    ....
  13. ncbi request reprint Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer
    Michelle S Yao
    Department of Radiation Oncology, University of Washington Medical School, Seattle, WA, USA
    Ann Surg Oncol 14:2985-93. 2007
    ..Internal mammary (IM) nodes are a potential site of breast lymphatic drainage. We examined the relationship between lymphoscintigraphic evidence of IM drainage and survival in early-stage breast cancer patients (pts)...
  14. ncbi request reprint Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
    ..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
  15. ncbi request reprint Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Jennifer R Bellon
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
    Am J Clin Oncol 27:407-10. 2004
    ..FDG-PET appears to be a useful noninvasive modality to detect IM metastases in LABC. Pathologic verification in a prospective study is necessary to confirm these findings...
  16. ncbi request reprint Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy
    David A Mankoff
    Division of Nuclear Medicine, Box 346113, University of Washington, 1959 E Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 43:500-9. 2002
    ....
  17. ncbi request reprint SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences
    Sylvain Beaulieu
    Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    J Nucl Med 44:1044-50. 2003
    ....
  18. ncbi request reprint Are we ready for dedicated breast imaging approaches?
    David A Mankoff
    Division of Nuclear Medicine, Box 356113, Room NN203, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 44:594-5. 2003
  19. ncbi request reprint Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET
    William B Eubank
    Department of Radiology S 113 RAD, Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108 1597, USA
    Radiographics 22:5-17. 2002
    ..FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases...
  20. ncbi request reprint Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy
    Stephanie E Stafford
    Division of Medical Oncology, University of Washington Medical Center, Seattle 98195, USA
    Acad Radiol 9:913-21. 2002
    ..The authors performed this study to determine the feasibility of using quantitative 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) to monitor the response of breast cancer bone metastases to therapy...